GlassScriptPhysician profile
Melody A Denson
NPI 1154394997
$35,641.72
in general payments reported to CMS, 2019-2025
58 companies · $6,642 in 2025
The $6,642 reported for 2025 was more than what 92% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $4,808 · 2021: $3,816 · 2022: $1,757 · 2023: $2,517 · 2024: $2,379 · 2025: $6,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,065 · Consulting Fee: $2,663 · Travel and Lodging: $741 · Education: $69.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,064.58 |
| Consulting Fee | $2,662.50 |
| Travel and Lodging | $740.98 |
| Education | $69.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $13,235.51 | 2019-2025 | Xtandi, Veozah, Myrbetriq |
| Medtronic, INC. | $6,751.65 | 2021-2025 | Interstim |
| Boston Scientific Corporation | $4,871.91 | 2019-2024 | Rezum Generator |
| Sumitomo Pharma America, INC. | $1,877.44 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $1,404.36 | 2019-2025 | Botox, Lupron Depot |
| Coloplast Corp | $1,263.63 | 2019-2025 | Saffron |
| Urovant Sciences INC | $606.58 | 2021-2022 | |
| Janssen Biotech, INC. | $567.28 | 2019-2025 | Erleada, Akeega, Balversa |
| Medtronic USA, INC. | $552.29 | 2019-2020 | |
| Allergan, INC. | $498.45 | 2019-2022 | |
| Pfizer INC. | $444.23 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $327.35 | 2019-2025 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $297.48 | 2019-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $267.73 | 2021-2025 | |
| Olympus America INC. | $224.87 | 2024-2025 | Itind System |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melody Denson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.